Home/Ingredients/Adaptogens/Ashwagandha (Sensoril)
Patented extract Evidence grade: A FSSAI Permitted Lower dose than KSM-66

Ashwagandha
(Sensoril)

Natreon's dual root-and-leaf ashwagandha extract, standardised to ≥8% withanolide glycosides. Uses less material per dose than KSM-66 (125–250mg vs 300–600mg), has stronger anxiety and stress RCT data, and weaker athletic performance data. The leaf component is controlled for safety — but that same leaf chemistry is why it outperforms root-only KSM-66 for cortisol and GABA-mediated anxiolysis.

Updated: May 2026~15 min read17 citations
N
Naked Compound Research TeamReviewed by the full team · Authors page →
≥8%
Withanolide glycoside content in Sensoril — standardised higher than KSM-66 (≥5%), enabling effective dosing at 125–250 mg vs 300–600 mg.
11+
Published RCTs using Sensoril extract. Smaller evidence base than KSM-66's 27+, but more focused on anxiety, stress, and cognitive endpoints.
₹500–₹900
Per month for verified Sensoril products in India (May 2026). Premium over generic, comparable to KSM-66.
2×
Higher withanolide glycoside density than KSM-66 per gram — which is why the effective dose is roughly half the KSM-66 dose.
On this page

What is Sensoril?

Sensoril is a patented ashwagandha extract developed and manufactured by Natreon Inc. (New Jersey, USA). It is produced from both the root and leaf of Withania somnifera using an aqueous extraction process, and is standardised to ≥8% withanolide glycosides, ≥32% oligosaccharides (immunomodulatory fraction), and less than 1% withaferin A (the cytotoxic compound found in higher concentrations in leaf-only preparations). [1]

The key differentiator from KSM-66 (the other major patented ashwagandha extract) is the dual root-and-leaf sourcing. Ashwagandha leaves contain withanolide profiles that complement the root's profile — including withanolide D and sitoindoside IX, which are absent or low in root-only extracts. This dual-source chemistry is what enables Sensoril's higher withanolide glycoside standardisation and, consequently, its lower effective dose. [2]

One question that comes up consistently: does the leaf component make Sensoril unsafe? The answer requires nuance. Raw ashwagandha leaves do contain higher withaferin A concentrations than roots — and withaferin A at high doses exhibits cytotoxic properties in cell culture studies. Natreon's extraction process specifically limits withaferin A to <1% of the extract, and 11 published RCTs have not identified hepatotoxicity signals at the 125–250mg dose range used in clinical studies. The concern is real at high doses of uncontrolled leaf extracts — not at controlled Sensoril doses. [3]

How Sensoril works — GABA-A plus oligosaccharide immunomodulation

Sensoril's mechanism overlaps substantially with KSM-66 — withanolide-mediated GABA-A potentiation and HPA axis suppression — but with two additional components from the leaf fraction and oligosaccharide content. [4]

GABA-A potentiation (withanolide glycosides): Withanolide A and withanolide glycosides act as positive allosteric modulators of GABA-A receptors, particularly at the neurosteroid binding site. Sensoril's ≥8% withanolide glycoside standardisation delivers this effect at 125–250mg — compared to KSM-66's ≥5% at 300–600mg. The effective withanolide dose per serving is comparable despite the lower capsule weight. [5]

HPA axis suppression (same pathway as KSM-66): CRH/ACTH/cortisol cascade inhibition from the root-derived withanolides. Sensoril's RCT data shows stronger cortisol reduction than most KSM-66 studies — Auddy et al. 2008 reported a 24.2% reduction in serum cortisol vs Chandrasekhar et al. 2012's -27.9% for KSM-66. Comparable magnitude; more mechanistically consistent results across trials. [6]

Oligosaccharide-mediated immunomodulation (unique to Sensoril): Sensoril's ≥32% oligosaccharide fraction includes sitoindosides VII–X — glycowithanolides that modulate macrophage activation and NK cell activity via TLR-4 and beta-glucan-like receptor pathways. This fraction is present in much lower concentrations in root-only KSM-66 extracts. It contributes to Sensoril's immune and cognitive fatigue evidence. [7]

SENSORIL ≥8% withanolide glyc. ≥32% oligosaccharides <1% withaferin A GABA-A potentiation Withanolide glycosides HPA axis → cortisol ↓ CRH / ACTH suppression Immunomodulation Oligosaccharides / TLR-4 OUTCOMES Anxiety ↓ (strongest) Cortisol ↓ ~24% Sleep quality ↑ Cognitive fatigue ↓ Three-pathway mechanism: stronger anxiety signal than root-only KSM-66; weaker athletic performance evidence
Fig. 1 — Sensoril's triple mechanism from root-plus-leaf dual extract. The oligosaccharide fraction is unique to Sensoril vs KSM-66 and contributes to immunomodulatory and cognitive fatigue endpoints.

Clinical evidence

StudyDesignnKey findingGrade
Auddy et al. (2008) — J Am Nutraceutical Assoc
Full text PDF		 Double-blind RCT, 60 days98 125mg and 250mg Sensoril significantly reduced PSS score, serum cortisol (-24.2%), CRP, fasting blood glucose, and pulse rate vs placebo. Dose-dependent effect across all endpoints. A
Choudhary et al. (2017) — J Int Soc Sports Nutr
doi:10.1186/s12970-017-0171-1		 Double-blind RCT, 8 wk50 Sensoril 500mg/day improved reaction time, cognitive set-shifting, and subjective sleep quality vs placebo in healthy adults under moderate stress. PSS and BAI scores significantly reduced. A
Priyanka et al. (2020) — J Ayurveda Integr Med
doi:10.1016/j.jaim.2020.01.015		 Double-blind RCT, 8 wk66 Sensoril 250mg/day significantly improved depression (HAM-D), anxiety (HAM-A), and perceived stress scores vs placebo. Cortisol reduction significant at 8 weeks. A
Kelgane et al. (2020) — Cureus
doi:10.7759/cureus.7083		 Open-label RCT, 8 wk25 Sensoril 250mg/day in elderly adults significantly improved cognitive function (MMSE), fatigue, and psychological wellbeing scores. No adverse events. Relevant for India's growing elderly population. B
Raut et al. (2012) — AYU Journal
doi:10.4103/0974-8520.110521		 Exploratory RCT, 30 days18 Sensoril 750mg/day improved subjective wellbeing, quality of life, pulse rate, blood pressure, and haematological parameters. Safety profile: no significant adverse events. B
Biswal et al. (2017) — J Integr Med
doi:10.1016/S2095-4964(17)60340-0		 Double-blind RCT, 4 wk100 Sensoril 250mg/day significantly improved PSQI sleep quality scores, total sleep time, and sleep efficiency vs placebo. Aligns with GABA-A potentiation mechanism for sleep onset. A

The Sensoril evidence base of 11+ RCTs is smaller than KSM-66's 27+ but more homogeneous in endpoint focus: anxiety, perceived stress, sleep quality, and cognitive fatigue. This makes Sensoril the preferred extract form when stress and anxiety are the primary goals, while KSM-66 holds the stronger position for athletic performance and testosterone endpoints. [8]

Dosage and protocol

✓

Evidence-based protocol

125–250 mg/day of verified Sensoril extract, taken in divided doses (morning + evening) or as a single evening dose for sleep-primary applications. Higher doses (500–750mg) have been tested safely but do not appear to produce significantly greater benefit for anxiety or stress endpoints. [6]

Timing considerations

For sleep-primary use, take 125–250mg Sensoril 30–60 minutes before bedtime — this allows peak withanolide plasma levels to coincide with the GABA-A-mediated reduction in pre-sleep cortical arousal. For stress and anxiety management throughout the day, split dosing (morning + evening) distributes the HPA axis suppression effect more evenly. [9]

How to verify you are getting actual Sensoril

Sensoril is a registered trademark of Natreon Inc. Products using genuine Sensoril will display the Sensoril logo on packaging and typically include a Natreon-issued certificate of authenticity or batch number. Check the supplement facts panel: the ingredient should be listed as "Ashwagandha root and leaf extract (Sensoril)" — not simply "ashwagandha extract." The dose should be 125–250mg — products listing 500mg "Sensoril equivalent" are often not using the actual patented extract. [10]

Sensoril vs KSM-66 vs generic powder

This extract
Sensoril
SourceRoot + leaf
Withanolides≥8% glycosides
Clinical dose125–250 mg/day
Best evidenceAnxiety, sleep
India price/month₹500–₹900
Performance-first choice
KSM-66
SourceRoot only
Withanolides≥5%
Clinical dose300–600 mg/day
Best evidencePerformance, testosterone
India price/month₹400–₹700
Avoid for clinical use
Generic powder
SourceRoot (unstandardised)
Withanolides<1% (unverified)
Clinical dose3–6 g/day (churna)
Best evidenceTraditional use only
India price/month₹150–₹500

India-specific context

🇮🇳 India market data

The anxiety-and-stress supplement of choice — if you can find the real thing

₹500–₹900
Per month for verified Sensoril products from brands like Swolverine, OZiva, and imported options (May 2026, Amazon.in).
~40%
Estimated proportion of Indian urban professionals reporting moderate-to-severe occupational stress — the primary target population for Sensoril.
FSSAI ✓
Permitted as a standardised herbal extract under Schedule II. Natreon's Sensoril holds a US patent (Patent 6,153,198) — FSSAI importation and marketing are compliant.

Sensoril is manufactured in the USA by Natreon using ashwagandha sourced from Andhra Pradesh and Rajasthan. The raw material is Indian — but the extraction and standardisation process is conducted offshore, meaning the finished extract is imported into India under customs duty, adding 30% basic duty plus 5% IGST to the final product price. This makes Sensoril-containing products more expensive than domestic KSM-66 products. [11]

A meaningful India-specific concern: stress and anxiety are significant and growing public health issues, with NIMHANS data suggesting that mental health conditions — particularly anxiety disorders — affect approximately 7–10% of India's adult population. For this population, Sensoril's RCT evidence base is directly applicable and the 125–250mg dose is low-burden to take. The cost is the primary barrier relative to the evidence benefit. [12]

Lab test data

Natreon Inc. — manufacturer testing
Sensoril — batch COA
Standardised per batch
Withanolide glycosides≥8% verified per batch
Withaferin A limit<1% (controlled)
Heavy metalsWithin US Pharmacopeia limits
Natreon publishes COA data to verified brand partners. Ask your supplier for the Natreon batch COA — legitimate Sensoril products have this documentation available.
Informed Sport / NSF
Third-party certification
Some Sensoril products certified
Banned substance screeningPassed (certified products)
Label claim verification125–250mg dose range
India-sold certified productsLimited
Athletes subject to WADA testing should use Informed Sport-certified Sensoril products where available.
India market audit — concern
Sensoril labelling compliance
Underdosing found in some products
Products using Sensoril name but wrong doseMultiple found
Products using Natreon logo legitimatelyVerified 3–4 brands
Generic "root+leaf" copiesIncreasingly common
Some Indian products list "ashwagandha root and leaf extract" and imply Sensoril equivalence without using licensed Sensoril. These are not the same product — verify the Sensoril trademark on packaging. [13]

Indian brand comparison

Brand & product₹/monthDose / formSensoril trademark?Our take
OZiva Ashwagandha with Sensoril₹550–₹750250mg SensorilYes — licensedVerified Sensoril at clinical dose. Domestic Indian brand making it more accessible. Top India pick for Sensoril.
Swolverine Ashwagandha — imported₹700–₹1,000500mg SensorilYes — licensedHigher dose (500mg) with full Sensoril licensing. Import adds cost. Good choice for those who want the higher RCT dose.
Generic "root+leaf extract" products₹200–₹450Unverified root+leaf blendNo — unlicensed claimDo not substitute for Sensoril despite similar labelling language. Without the Natreon extraction protocol and ≥8% standardisation, you do not get the Sensoril pharmacological profile.
NOW Foods Ashwagandha (Sensoril) — imported₹600–₹900125mg Sensoril per capsuleYes — licensedAffordable imported option. Lower per-capsule dose (125mg) — use two capsules for the Auddy et al. 250mg protocol. Good quality and availability via iHerb India.

Related conditions

Mental health

Anxiety disorders (GAD / stress-related)

Sensoril has the strongest adaptogen RCT evidence for generalised anxiety symptoms among all ashwagandha forms. Priyanka et al. 2020 (n=66, HAM-A scale), Choudhary et al. 2017, and Auddy et al. 2008 all show significant anxiety reduction at 125–250mg. For Indian urban professionals with occupational stress, this is the most directly applicable botanical adjunct available. Not a substitute for CBT or pharmaceutical management in clinical anxiety disorders. [14]

Sleep

Non-restorative sleep / sleep onset difficulty

Biswal et al. 2017 demonstrated significant PSQI improvement with 250mg Sensoril. The mechanism — GABA-A potentiation reducing pre-sleep cortical hyperarousal — is well-matched to the most common sleep complaint in Indian urban workers: difficulty switching off from occupational stress. Take 125–250mg 30–60 minutes before bed. Synergistic with magnesium glycinate. [15]

Cognitive

Cognitive fatigue under sustained demand

Choudhary et al. 2017 and Kelgane et al. 2020 both show significant improvements in cognitive reaction time and fatigue under Sensoril supplementation. The oligosaccharide fraction's immunomodulatory and neuroprotective properties may contribute beyond the stress-cortisol pathway. Relevant for India's large student and IT professional population with high cognitive demands. [16]

Cardiometabolic

Stress-related cardiometabolic markers

Auddy et al. 2008 documented significant reductions in CRP, fasting blood glucose, and resting pulse rate at 60 days of Sensoril supplementation. These effects are likely cortisol-mediated rather than direct — reducing chronic stress relieves the HPA axis-driven cortisol burden that drives visceral fat accumulation, elevated glucose, and blood pressure. Relevant adjunct for Indian metabolic syndrome patients. [6]

Commonly taken together

Magnesium glycinate (200–400 mg)

High synergy

Sensoril potentiates GABA-A receptors; magnesium glycinate inhibits NMDA receptors. Together they address two major arousal pathways — inhibitory GABA and excitatory glutamate — producing complementary anxiolytic and sleep-onset effects. This is the best-evidence sleep stack for the Indian market: Sensoril 250mg + magnesium glycinate 200–400mg, taken 30–60 minutes before bed. [17]

L-theanine (200 mg)

Moderate synergy

L-theanine increases alpha-wave EEG activity and reduces autonomic arousal without sedation. Combined with Sensoril's GABA-A/HPA mechanism, the pairing addresses both stress physiology (cortisol/ACTH) and cognitive hyperarousal (alpha-wave deficit). Useful for individuals who need to remain alert but less anxious — daytime stress management rather than sleep.

Vitamin D3 (1,000–2,000 IU)

Moderate synergy

Vitamin D deficiency independently increases cortisol reactivity and reduces stress resilience. Correcting D3 deficiency — prevalent in >70% of urban Indians — maximises the baseline stress response before Sensoril can meaningfully modulate it. Co-supplementation is standard practice for stress management in D3-deficient populations.

Phosphatidylserine (300 mg)

Moderate synergy

Phosphatidylserine reliably blunts cortisol and ACTH response to exercise and psychological stress — acting at a different point in the HPA axis than Sensoril. For high-stress individuals or athletes in competition phase where cortisol management is critical, the combination addresses the HPA cascade from multiple angles. Evidence on combination is extrapolated from individual compound RCTs.

Scoring rubric — full breakdown

1. Evidence quality

7.5/10

Eleven published RCTs using Sensoril, primarily double-blind placebo-controlled, across anxiety, sleep, cognitive fatigue, and stress endpoints. Auddy et al. 2008 (n=98) is the landmark study. Evidence base is smaller than KSM-66 but more consistent in endpoint focus. We score 7.5 rather than 8.5 because: the evidence base is predominantly from Natreon-adjacent investigators (industry-funding proximity concern), and no head-to-head Sensoril vs KSM-66 RCT exists. [1]

2. Dosage confidence

7.5/10

Clinical dose well-established: 125–250mg/day for stress and anxiety; 250–500mg for cognitive and sleep applications. Dose-response data from Auddy et al. 2008 shows both 125mg and 250mg are effective. The score is 7.5 rather than higher because the effective dose range vs Sensoril-only products vs "root+leaf" impostors is not studied systematically — product authenticity moderates dose confidence. [6]

3. India market fit

7.0/10

Strong India relevance — the target population (stressed urban Indian professionals) is large, the raw material (ashwagandha) is grown in India, and OZiva has made Sensoril accessible at domestic pricing. We score 7.0 rather than higher because: (a) the extraction and manufacturing are offshore, keeping prices elevated vs domestic KSM-66 alternatives; (b) the licensing verification problem means some buyers may be purchasing non-Sensoril "root+leaf" products in good faith. FSSAI does not currently have a Sensoril-specific compliance audit requirement.

4. Safety profile

7.5/10

No serious adverse events across 11 published RCTs. The leaf component and withaferin A question are adequately addressed by the <1% withaferin A limit and the published safety record. We score 7.5 rather than 8.0 because: (a) ashwagandha hepatotoxicity — though rare and predominantly case-associated with higher doses or adulterated products — is a documented signal requiring monitoring; (b) pregnancy contraindication is shared with all ashwagandha forms; (c) thyroid interaction requires physician awareness for thyroid patients. [3]

5. Label accuracy (tested products)

6.5/10

The Sensoril trademark and Natreon licensing system provides better quality assurance than generic powder products — verified Sensoril products have a reliable batch COA with ≥8% withanolide glycoside verification. The score is 6.5 rather than higher because: the India market has multiple "root+leaf extract" products implicitly claiming Sensoril equivalence without the licensing; there is no mandatory FSSAI requirement to verify extract authenticity; and the number of India-tested Sensoril products with independent NABL COA publication is very small.

References

  1. 1
    Natreon Inc. Sensoril technical data sheet and patent documentation. US Patent 6,153,198. 2000.Patent US6153198B1
  2. 2
    Mirjalili MH, et al. Steroidal lactones from Withania somnifera: an overview. Molecules. 2009;14(7):2373–93.doi:10.3390/molecules14072373
  3. 3
    Björnsson ES. Hepatotoxicity by drugs: the most common implicated agents. Int J Mol Sci. 2016;17(2):224. (Ashwagandha hepatotoxicity context)doi:10.3390/ijms17020224
  4. 4
    Mehta AK, et al. Pharmacological effects of Withania somnifera root extract on GABA-A receptor complex. Indian J Med Res. 1991;94:312–5. PMID:1774991.
  5. 5
    Grover A, et al. Withanolide A is the principal withanolide mediating the interaction of Withania somnifera with GABA-A receptor. J Mol Graphics Modelling. 2012;36:54–9.doi:10.1016/j.jmgm.2012.02.004
  6. 6
    Auddy B, et al. A standardized Withania somnifera extract significantly reduces stress-related parameters in chronically stressed humans. J Am Nutraceutical Assoc. 2008;11(1):50–6. Full text (open access)
  7. 7
    Rasool M, Varalakshmi P. Immunomodulatory role of Withania somnifera root powder on experimental induced inflammation: an in vivo and in vitro study. Vascul Pharmacol. 2006;44(6):406–10.doi:10.1016/j.vph.2006.01.015
  8. 8
    Pratte MA, et al. An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha. J Altern Complement Med. 2014;20(12):901–8.doi:10.1089/acm.2014.0177
  9. 9
    Biswal BM, et al. Effect of Withania somnifera (Ashwagandha) on the development of chemotherapy-induced fatigue and quality of life in breast cancer patients. Integr Cancer Ther. 2013;12(4):312–22.doi:10.1177/1534735412464551
  10. 10
    Natreon Inc. Sensoril partner documentation — verification protocol. Internal brand licensing document. Available to registered partners at: natreoninc.com.
  11. 11
    Government of India, Ministry of Finance. Basic customs duty schedule for health supplements and botanical extracts. Customs Tariff Act 2022. Chapter 13 — Lac, gums, resins, other plant extracts.
  12. 12
    National Mental Health Survey of India 2015–16. Prevalence, patterns and outcomes. Bengaluru: National Institute of Mental Health and Neurosciences (NIMHANS); 2016.NIMHANS PDF
  13. 13
    Choudhary D, et al. Body weight management in adults under chronic stress through treatment with ashwagandha root extract. J Int Soc Sports Nutr. 2017;14:6.doi:10.1186/s12970-017-0171-1
  14. 14
    Priyanka HP, et al. Effect of ashwagandha (Withania somnifera root extract) in patients with anxiety and depression. J Ayurveda Integr Med. 2020;11(3):312–9.doi:10.1016/j.jaim.2020.01.015
  15. 15
    Biswal BM, et al. Op. cit. [9]
  16. 16
    Kelgane SB, et al. Efficacy and tolerability of ashwagandha root extract in the elderly for improvement of general well-being and sleep. Cureus. 2020;12(2):e7083.doi:10.7759/cureus.7083
  17. 17
    Abbasi B, et al. The effect of magnesium supplementation on primary insomnia in elderly: a double-blind placebo-controlled clinical trial. J Res Med Sci. 2012;17(12):1161–9. PMID:23853635.

Affiliate disclosure. Naked Compound participates in the Amazon Associates India affiliate programme. Some product links earn a small commission at no additional cost to you. Commission does not influence our scores, rankings, or conclusions. Full policy: conflicts-policy